Evidence map›Paper›PMID 38904041›Full record

ArticleFrontiers in endocrinology2024

Association between triglyceride glucose index and breast cancer in 142,184 Chinese adults: findings from the REACTION study.

Xueyan Wu, Shuangyuan Wang, Lin Lin, Xiaojing Jia, Chunyan Hu, Hongyan Qi, Hong Lin, Ruizhi Zheng, Mian Li, Yu Xu and 40 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

Xueyan Wu *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shuangyuan Wang *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lin Lin *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaojing JiaDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chunyan HuDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hongyan QiDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hong LinDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ruizhi ZhengDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mian LiDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu XuDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Min XuDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lulu ChenUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Tianshu ZengUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ruying HuInstitute of Chronic Diseases, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Zhen YeInstitute of Chronic Diseases, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Lixin ShiDepartment of Endocrinology, Affiliated Hospital of Guiyang Medical College, Guiyang, China.
Qing SuXinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Xuefeng YuTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Li YanSun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Tiange WangDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhiyun ZhaoDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jie ZhengDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Guijun QinDepartment of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qin WanDepartment of Endocrinology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Gang ChenFujian Provincial Hospital, Fujian Medical University, Fuzhou, China.
Meng DaiDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xulei TangDepartment of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, China.
Zhengnan GaoDepartment of Endocrinology, Dalian Municipal Central Hospital, Dalian, China.
Feixia ShenDepartment of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xuejiang GuDepartment of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Zuojie LuoDepartment of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yingfen QinDepartment of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Li ChenDepartment of Endocrinology, Qilu Hospital of Shandong University, Jinan, China.
Xinguo HouDepartment of Endocrinology, Qilu Hospital of Shandong University, Jinan, China.
Yanan HuoDepartment of Endocrinology, Jiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang, China.
Qiang LiDepartment of Endocrinology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Guixia WangDepartment of Endocrinology, The First Hospital of Jilin University, Changchun, China.
Yinfei ZhangDepartment of Endocrinology, Central Hospital of Shanghai Jiading District, Shanghai, China.
Chao LiuDepartment of Endocrinology, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China.
Youmin WangDepartment of Endocrinology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Shengli WuDepartment of Endocrinology, Karamay Municipal People's Hospital, Xinjiang, China.
Tao YangDepartment of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Huacong DengDepartment of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jiajun ZhaoDepartment of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Yiming MuDepartment of Endocrinology, Chinese People's Liberation Army General Hospital, Beijing, China.
Guang NingDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weiqing WangDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yufang BiDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuhong ChenDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jieli LuDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The triglyceride glucose (TyG) index has been associated with an increased risk in breast cancer. However, this association remains unclear among the Chinese population. This study aimed to investigate whether the TyG index is associated with the risk of prevalent breast cancer in Chinese women. Methods: This cross-sectional study included 142,184 women from the REACTION (Risk Evaluation of Cancers in Chinese Diabetic Individuals: A Longitudinal) Study, which recruited adults aged 40 years or older from 25 centers across mainland China between 2011 and 2012. The TyG index was calculated according to the formula: Ln (fasting triglycerides [mg/dL] × fasting glucose [mg/dL]/2). Multivariable-adjusted logistic regression models were used to evaluate odds ratios (ORs) and 95% confidence intervals (CIs) regarding the associations between the TyG index and breast cancer. Results: Multivariable-adjusted logistic regression analysis showed that compared with the lowest quartile of the TyG index, the highest quartile of the TyG index was significantly associated with an increased risk of prevalent breast cancer, with an OR (95% CI) of 1.61 (1.19-2.17). In the stratified analysis, the association of each 1 SD increase in the TyG index with risk of prevalent breast cancer was more dominant in individuals with menarche at age 13-17, those who were postmenopausal, those with a history of breastfeeding, and those who had two to four children, with the ORs (95% CIs) of 1.35 (1.09-1.68), 1.27 (1.05-1.54), 1.26 (1.05-1.52), and 1.32 (1.08-1.62), respectively. Moreover, among those without discernible insulin resistance (homeostatic model assessment-insulin resistance [HOMA-IR] ≥2.5), hyperglycemia and dyslipidemia, each 1 SD increase in the TyG index was associated with a 1.36-fold increase in breast cancer risk, with an OR (95% CI) of 2.36 (1.44-3.87). Conclusion: The TyG index is significantly associated with the prevalent breast cancer risk among middle-aged and elderly Chinese women.

Indexed as

Blood GlucoseBreast NeoplasmsTriglyceridesAdultAgedChinaCross-Sectional StudiesEast Asian PeopleFemaleHumansLongitudinal StudiesMiddle AgedRisk FactorsBlood GlucoseTriglyceridesbreast cancerChinese populationglucoseinsulin resistancetriglyceride

Identifiers

PMID38904041
PMCPMC11186986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.